Sign In
Buy ELVN
$36.03
+0.510 (+1.44%)
At Close: Jun 03, 2026
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 09'th Sep 2025
Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
10:55am, Wednesday, 27'th Aug 2025
The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend i
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
06:20pm, Monday, 25'th Aug 2025
BOULDER, Colo. , Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
04:05pm, Wednesday, 13'th Aug 2025
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety a
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
10:56am, Friday, 18'th Jul 2025
The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
BOULDER, Colo. , June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
09:30am, Friday, 13'th Jun 2025
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
06:10am, Friday, 13'th Jun 2025
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
06:02am, Friday, 13'th Jun 2025
Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::
Enliven Therapeutics to Present at Upcoming Investor Conferences
04:05pm, Thursday, 22'nd May 2025
BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
04:05pm, Wednesday, 14'th May 2025
Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26%
Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::A
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
04:03pm, Wednesday, 02'nd Apr 2025
BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
04:05pm, Thursday, 13'th Mar 2025
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
04:05pm, Tuesday, 25'th Feb 2025
BOULDER, Colo. , Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development o
